"Bio-Works is very pleased to be able to support 3P Biopharmaceutics in their mission to deliver advanced drugs to improve lives," says Jonathan Royce, CEO of Bio-Works Technologies. This order also confirms that our investment in continued establishment in Europe is progressing according to plan.”

3P Biopharmaceuticals is a global contract development and manufacturing organization (CDMO) specializing in the manufacture of biological drugs and cell therapy products. Based in Pamplona, Spain, they provide clinical and commercial manufacturing of biological drugs at their GMP-approved facilities.

Toleranzia AB (publ) develops drugs that harness the power of the immune system for the treatment of autoimmune orphan diseases. The drugs, which target the cause of the disease, can alleviate or cure the disease and not, like current treatments, merely reduce the symptoms. They have the potential to be the first long-acting or curative therapies that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia’s shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, 08 503 015 50, CA@mangold.se, is the Company’s Certified Adviser.